CRDF

Cardiff Oncology, Inc.

Nasdaq · Biological Products, (No Diagnostic Substances) · EDGAR filings (CIK 1213037) · 3 signals · 1 setups · updated Aug 16, 2026

What the filings say Pressure ▼

The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.

Radar 52 (elevated attention) · dilution pressure elevated · listing risk low · governance risk low · runway 10.7 mo · strongest signal: Registered direct (Aug 11, 2026)

What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).

Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.

52Radar · attention score (0–100)

48Dilution pressure · financing + balance sheet

0Listing risk · exchange standards

25Governance risk · reporting, auditor, going concern

Setups

Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.

Forced-raise setup Pressure ▼ strength 0.70

The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (runway 6–12 months) coexists with live selling machinery (registered direct). Base case is a discounted raise; the question is when, not if.

Would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
Would invalidate: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).

Registered directRunway 6–12 months

Analyst note

No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.

Pro on CRDF

Alerts

One email the morning CRDF files anything that matches your rules (types, minimum score, setups).

12-month history

Every signal and setup for CRDF back a year, not just 30 days — see how the current setup built.

Full analyst notes

What we noticed, evidence with links, what could prove us wrong, red-team caveats.

Full screener + CSV

All 985 flagged companies, same-day, sortable and exportable.

Get Pro · $18.85/mo founding rate See a full Pro morning 35% off forever until Sept 30 · cancel any time

Balance sheet (XBRL)

$9.2Mcash + short-term investments as of Jun 30, 2026

10.7 moestimated runway (annualized 180-day YTD operating cash flow [companyfacts])

$26.5Mstockholders' equity as of Jun 30, 2026

$205.4Mpublic float (10-K cover)

77.8Mshares outstanding as of Aug 6, 2026 · was 68.4M Apr 30, 2026

Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 47 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.

Signal timeline

Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.

Date	Signal	Evidence	Score
Aug 11, 2026	▼ Registered direct	“rdo” language in 8-K (EX-99.1) filed 2026-08-11 filing	36
Aug 11, 2026	▼ Going-concern language	“going concern periodic” language in 10-Q (10-Q) filed 2026-08-11 filing	25
Jun 30, 2026	▼ Runway 6–12 months	~10.7 months runway: liquidity $43,641,000 (cash $9,197,000 + investments $34,444,000) as of 2026-06-30, burn $48,774,139/yr (annualized 180-day YTD operating cash flow [companyfacts]) filing	23

Other forced raise setups

VIVS VivoSim Labs, INC. · HCWB HCW Biologics Inc. · CYCU Cycurion, Inc. · BIAF bioAffinity Technologies, In · XHLD TEN Holdings, Inc. · VSEE VSEE HEALTH, INC. · screener →

Not a subscriber yet? The free morning digest carries what changed and the top setups. Subscribe free → · Compare plans